Isoform Positions

Isoform Protein Position Transcript Position Chromosomal Position (HG38) Chromosomal Position (HG19)
IC26278104;8105;8106 chr2:178771448;178771447;178771446chr2:179636175;179636174;179636173
N2AB26278104;8105;8106 chr2:178771448;178771447;178771446chr2:179636175;179636174;179636173
N2A26278104;8105;8106 chr2:178771448;178771447;178771446chr2:179636175;179636174;179636173
N2B25817966;7967;7968 chr2:178771448;178771447;178771446chr2:179636175;179636174;179636173
Novex-125817966;7967;7968 chr2:178771448;178771447;178771446chr2:179636175;179636174;179636173
Novex-225817966;7967;7968 chr2:178771448;178771447;178771446chr2:179636175;179636174;179636173
Novex-326278104;8105;8106 chr2:178771448;178771447;178771446chr2:179636175;179636174;179636173

Information

  • RefSeq wild type amino acid: T
  • RefSeq wild type transcript codon: ACA
  • RefSeq wild type template codon: TGT
  • Domain: Ig-16
  • Domain position: 7
  • Structural Position: 9
  • Q(SASA): 0.5591
  • Predicted PPI site: N

Reported SAVs

SNV RS
DUET
PolyPhen-2
Condel
Rhapsody
REVEL
MVP
Source
MAF
Disease
Zygosity
Site annotation
mCSM PPI
Predicted PPI site
Comments
AFR
AMR
AMS
ASJ
EAS
EUR
FIN
MDE
NFE
SAS
OTH
T/A rs1451021817 -0.59 0.002 N 0.123 0.275 0.137902524267 gnomAD-2.1.1 3.98E-06 None None None None N None 0 0 None 0 0 None 3.27E-05 None 0 0 0
T/A rs1451021817 -0.59 0.002 N 0.123 0.275 0.137902524267 gnomAD-4.0.0 1.59111E-06 None None None None N None 0 0 None 0 0 None 0 0 0 1.43283E-05 0

Saturation Mutagenesis

SAV
AlphaMissense (IC)
AlphaMissense Class (IC)
AlphaMissense (N2AB)
AlphaMissense Class (N2AB)
mCSM
mCSM class
PolyPhen-2
PolyPhen-2 Class
Rhapsody
Rhapsody Class
Condel
Condel Score
Site annotation
mCSM PPI
Predicted PPI site
T/A 0.076 likely_benign 0.0765 benign -0.744 Destabilizing 0.002 N 0.123 neutral N 0.450708242 None None N
T/C 0.3456 ambiguous 0.3364 benign -0.43 Destabilizing 0.995 D 0.475 neutral None None None None N
T/D 0.277 likely_benign 0.2698 benign 0.133 Stabilizing 0.704 D 0.471 neutral None None None None N
T/E 0.181 likely_benign 0.1706 benign 0.112 Stabilizing 0.329 N 0.431 neutral None None None None N
T/F 0.1746 likely_benign 0.1715 benign -0.922 Destabilizing 0.944 D 0.501 neutral None None None None N
T/G 0.2158 likely_benign 0.2195 benign -0.968 Destabilizing 0.329 N 0.433 neutral None None None None N
T/H 0.176 likely_benign 0.1702 benign -1.213 Destabilizing 0.017 N 0.322 neutral None None None None N
T/I 0.0954 likely_benign 0.0939 benign -0.252 Destabilizing 0.473 N 0.461 neutral N 0.508555009 None None N
T/K 0.1239 likely_benign 0.1147 benign -0.61 Destabilizing 0.006 N 0.247 neutral N 0.426665071 None None N
T/L 0.0771 likely_benign 0.0767 benign -0.252 Destabilizing 0.329 N 0.431 neutral None None None None N
T/M 0.0813 likely_benign 0.0799 benign -0.075 Destabilizing 0.944 D 0.496 neutral None None None None N
T/N 0.1052 likely_benign 0.1013 benign -0.459 Destabilizing 0.704 D 0.324 neutral None None None None N
T/P 0.2613 likely_benign 0.2037 benign -0.385 Destabilizing 0.784 D 0.531 neutral N 0.512009505 None None N
T/Q 0.1495 likely_benign 0.1457 benign -0.617 Destabilizing 0.085 N 0.215 neutral None None None None N
T/R 0.1087 likely_benign 0.0991 benign -0.378 Destabilizing 0.473 N 0.471 neutral N 0.475195076 None None N
T/S 0.0974 likely_benign 0.0992 benign -0.75 Destabilizing 0.023 N 0.149 neutral N 0.482664071 None None N
T/V 0.09 likely_benign 0.0887 benign -0.385 Destabilizing 0.007 N 0.175 neutral None None None None N
T/W 0.466 ambiguous 0.4444 ambiguous -0.861 Destabilizing 0.995 D 0.503 neutral None None None None N
T/Y 0.2221 likely_benign 0.2062 benign -0.627 Destabilizing 0.893 D 0.529 neutral None None None None N

Titin has multiple isoforms, the longest being the theoretical IC (inferred complete) isoform which contains all 363 in-frame titin exons. Here all isoform positions have been mapped onto the IC sequence, with an exception being the C-terminal of the much shorter novex-3 isoform. This contains the out of frame exon 48 which cannot be mapped to the other isoforms.